IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued on Saturday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 4.2 %

Shares of NASDAQ:IRIX opened at $1.38 on Friday. IRIDEX has a 52-week low of $1.27 and a 52-week high of $3.65. The stock has a market cap of $22.96 million, a P/E ratio of -2.06 and a beta of 0.84. The business has a fifty day moving average of $1.63 and a two-hundred day moving average of $1.71. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.